Department of Ophthalmology, Glostrup Hospital, Glostrup, Denmark.
Am J Ophthalmol. 2012 Feb;153(2):209-213.e2. doi: 10.1016/j.ajo.2011.10.016.
To report incidence rates of legal blindness from age-related macular degeneration (AMD) and other causes in Denmark from years 2000 to 2010 in the age group at risk of AMD aged 50 years and older.
Population-based observational registry study.
settings: Membership register of the Danish Association of the Blind, the primary admission criterion of which is best-corrected visual acuity 0.1 (20/200) or lower in a person's better-seeing eye. study population: A total of 11 848 incident cases of legal blindness from a population of citizens aged ≥50 years numbering 1.71 million in 2000 and 1.87 million in 2010 with free access to a single-payer public health care system. main outcome measures: Incidence rates of legal blindness from AMD from 2000 to 2010.
The incidence rate of legal blindness attributable to AMD in citizens aged ≥50 years decreased from 52.2 cases per year per 100 000 in 2000 to 25.7 cases per year per 100 000 in 2010, corresponding to a reduction of 50% (95% confidence interval [CI(95)]: 45%-56%, P < .0001, adjusted for age), the bulk of the reduction occurring after 2006. The incidence of legal blindness from causes other than AMD decreased by 33% (CI(95): 21%-44%, P < .0001), most of the reduction occurring between 2000 and 2006.
From 2000 to 2010 the incidence of legal blindness from AMD fell to half the baseline incidence. The bulk of the reduction occurred after the introduction of intravitreally injected inhibitors of vascular endothelial growth factor in 2006.
报告 2000 至 2010 年丹麦 50 岁及以上年龄组与年龄相关性黄斑变性（AMD）相关的法律失明发病率以及其他原因引起的法律失明发病率。
基于人群的观察性登记研究。
研究地点：丹麦盲人协会成员登记处，主要入选标准为最佳矫正视力（BCVA）在较好眼为 0.1（20/200）或更低的人。研究人群：2000 年和 2010 年共有 11848 例新诊断的法律失明病例，2000 年的研究人群为 50 岁及以上的公民 171 万，2010 年为 187 万，这些公民均可免费获得单一付款人公共医疗保健系统。主要观察指标：2000 年至 2010 年 AMD 导致的法律失明发病率。
50 岁及以上公民中 AMD 导致的法律失明发病率从 2000 年的每年每 10 万人 52.2 例降至 2010 年的每年每 10 万人 25.7 例，降幅为 50%（95%置信区间[CI95]：45%-56%，P <.0001，校正年龄后），大部分降幅发生在 2006 年之后。除 AMD 以外的其他原因导致的法律失明发病率下降了 33%（CI95：21%-44%，P <.0001），大部分降幅发生在 2000 年至 2006 年之间。
2000 年至 2010 年，AMD 导致的法律失明发病率降至基线发病率的一半。大部分降幅发生在 2006 年血管内皮生长因子抑制剂玻璃体腔内注射治疗引入之后。
